Skip to main content

Patient & Practice Resources

Images are not of actual patients

Tools and information for you and your adult patients with generalized myasthenia gravis (gMG)

Filter By Category:

Showing: All Resources

HCP Resources

HCP Starter Kit

A selection of resources designed to help you and your practice start the initiation process.

Download Patient & Prescriber Start Form Download New Patient Checklist Download REMS QR Form Download OneSource™ Brochure

Dosing and Administration Guide

Step-by-step instructions for initiating ULTOMIRIS® (ravulizumab-cwvz) weight-based dosing.

Download Dosing and Administration Guide

Vaccination Q&A Brochure

Answers to common questions about the vaccination requirements for ULTOMIRIS treatment.

Download Vaccination Q&A Brochure

Assessment Tool Booklet

Tools to help you and your practice track patients’ symptoms over time.

Download Assessment Tool Booklet

Initiation Guide

This comprehensive resource provides an overview of topics when commencing treatment for gMG, such as prescribing ULTOMIRIS for appropriate patients; dosing guidelines, including weight-based dosing; ordering, storing, and administering ULTOMIRIS; vaccination prior to ULTOMIRIS treatment; the REMS program; OneSource; and the CoPay Program.

Download Initiation Guide

HCP Patient Discussion Guide

A discussion guide that provides patient-friendly answers to frequently asked questions about ULTOMIRIS.

Download HCP Patient Discussion Guide

ULTOMIRIS Safety and Efficacy Brochure

This brochure provides further details on the safety profile and efficacy data of ULTOMIRIS.

Sample Letter of Medical Necessity

This is a sample letter that may be used to communicate why treatment with ULTOMIRIS is medically necessary.

Download Sample Letter of Medical Necessity

Access and Coverage Guide

This provides details about the access opportunities that gMG patients nationwide have available to them.

Download Access and Coverage Guide

Patient Case Study: Using ULTOMIRIS in Recently Diagnosed Patients

Do you have gMG patients like Madison? Learn about her story and the types of patients for whom ULTOMIRIS might be appropriate.

Download “Do you have patients like Madison?” Brochure

Guide to ULTOMIRIS and Corticosteroids in gMG

A brochure detailing the data on use of corticosteroids, and how treatment with ULTOMIRIS may help patients reduce use.

Download Guide to ULTOMIRIS and Corticosteroids in gMG

ULTOMIRIS Clinical Pharmacology Brochure

A brochure featuring ULTOMIRIS PK/PD data, including analysis of ULTOMIRIS data in anti-AChR antibody-positive gMG captured throughout the CHAMPION study.

Patient Resources

Vaccination Card

As part of the REMS program, this card highlights the risk of meningococcal infection for gMG patients taking ULTOMIRIS® (ravulizumab-cwvz) and underscores the importance of meningococcal vaccination.

Download Vaccination Card

Patient ER Checklist

Patients treated with ULTOMIRIS should bring this resource with them on arrival to an emergency room for use by physicians and/or first responders.

Download Patient ER Checklist

Patient Brochure

This brochure provides patients and caregivers with clear, concise information about ULTOMIRIS, including how it works and what they can expect when starting treatment.

Download Patient Brochure

REMS Patient Safety Brochure

As part of the REMS program, it is essential to inform patients on ULTOMIRIS about the risk of meningococcal infection and steps to take in the case of adverse events.

Download REMS Patient Safety Brochure

REMS Patient Safety Card

A feature of the REMS program, this card highlights the risk of meningococcal infection for gMG patients taking ULTOMIRIS and provides them information should adverse events occur.

Download REMS Patient Safety Card

Patient-Doctor Discussion Guide

This guide provides patients with some common questions and talking points to discuss at their next healthcare appointment.

Download Patient-Doctor Discussion Guide

gMG, generalized myasthenia gravis; PD, pharmacodynamics; PK, pharmacokinetics; REMS, Risk Evaluation and Mitigation Strategy.

Need help starting patients on ULTOMIRIS, additional resources, or ongoing support?

Contact an Alexion Account Manager

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

ULTOMIRIS, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1)] Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

  • Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of ULTOMIRIS, unless the risks of delaying ULTOMIRIS therapy outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor. See Warnings and Precautions (5.1) for additional guidance on the management of the risk of serious infections caused by meningococcal bacteria.
  • Patients receiving ULTOMIRIS are at increased risk for invasive disease caused by Neisseria meningitidis, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected.

Because of the risk of serious meningococcal infections, ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ULTOMIRIS and SOLIRIS REMS [see Warnings and Precautions (5.2)].

Alexion Connect

Healthcare Professionals: Answers to your questions are a phone call away!

Connect with a live ULTOMIRIS representative at 1-833-445-2111 or online at Contact an Account Manager.

Get Support

CONTRAINDICATIONS

  • Initiation in patients with unresolved serious Neisseria meningitidis infection.

WARNINGS AND PRECAUTIONS

Serious Meningococcal Infections

ULTOMIRIS, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors.

Revaccinate patients in accordance with ACIP recommendations considering the duration of ULTOMIRIS therapy. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent ULTOMIRIS therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including ULTOMIRIS. The benefits and risks of treatment with ULTOMIRIS, as well as those associated with antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by Neisseria meningitidis.

Vaccination does not eliminate the risk of serious meningococcal infections, despite development of antibodies following vaccination.

Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if they occur. Promptly treat known infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of ULTOMIRIS in patients who are undergoing treatment for serious meningococcal infection depending on the risks of interrupting treatment in the disease being treated.

ULTOMIRIS and SOLIRIS REMS
Due to the risk of serious meningococcal infections, ULTOMIRIS is available only through a restricted program called ULTOMIRIS and SOLIRIS REMS.

Prescribers must enroll in the REMS, counsel patients about the risk of serious meningococcal infection, provide patients with the REMS educational materials, assess patient vaccination status for meningococcal vaccines (against serogroups A, C, W, Y, and B) and vaccinate if needed according to current ACIP recommendations two weeks prior to the first dose of ULTOMIRIS. Antibacterial drug prophylaxis must be prescribed if treatment must be started urgently, and the patient is not up to date with both meningococcal vaccines according to current ACIP recommendations at least two weeks prior to the first dose of ULTOMIRIS. Patients must receive counseling about the need to receive meningococcal vaccines and to take antibiotics as directed, signs and symptoms of meningococcal infection, and be instructed to carry the Patient Safety Card at all times during and for 8 months following ULTOMIRIS treatment.

Further information is available at www.UltSolREMS.com or 1-888-765-4747.

Other Infections
Serious infections with Neisseria species (other than Neisseria meningitidis), including disseminated gonococcal infections, have been reported.

ULTOMIRIS blocks terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria, such as infections caused by Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae. Patients receiving ULTOMIRIS are at increased risk for infections due to these organisms, even if they develop antibodies following vaccination.

Thromboembolic Event Management
The effect of withdrawal of anticoagulant therapy during treatment with ULTOMIRIS has not been established. Treatment should not alter anticoagulant management.

Infusion-Related Reactions
Intravenous administration may result in systemic infusion-related reactions, including anaphylaxis and hypersensitivity reactions. In clinical trials, infusion-related reactions occurred in approximately 1 to 7% of patients treated with ULTOMIRIS. These events included lower back pain, drop in blood pressure, limb discomfort, drug hypersensitivity (allergic reaction), dysgeusia (bad taste), and drowsiness. These reactions did not require discontinuation of ULTOMIRIS. If signs of cardiovascular instability or respiratory compromise occur, interrupt ULTOMIRIS infusion and institute appropriate supportive measures.

ADVERSE REACTIONS
Most common adverse reactions in adult patients with gMG (incidence ≥10%) were diarrhea and upper respiratory tract infection. Serious adverse reactions were reported in 20 (23%) of patients treated with ULTOMIRIS and in 14 (16%) patients receiving placebo. The most frequent serious adverse reactions were infections reported in at least 8 (9%) patients treated with ULTOMIRIS and in 4 (4%) patients treated with placebo. Of these infections, one fatal case of COVID-19 pneumonia was identified in a patient treated with ULTOMIRIS and one case of infection led to discontinuation of ULTOMIRIS.

DRUG INTERACTIONS
Plasma Exchange, Plasmapheresis, and Intravenous Immunoglobulins
Concomitant use of ULTOMIRIS with plasma exchange (PE), plasmapheresis (PP), or intravenous immunoglobulin (IVIg) treatment can reduce serum ravulizumab concentrations and requires a supplemental dose of ULTOMIRIS.

Neonatal Fc Receptor Blockers
Concomitant use of ULTOMIRIS with neonatal Fc receptor (FcRn) blockers (e.g., efgartigimod) may lower systemic exposures and reduce effectiveness of ULTOMIRIS. Closely monitor for reduced effectiveness of ULTOMIRIS.

INDICATION
ULTOMIRIS is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

To report SUSPECTED ADVERSE REACTIONS, contact Alexion Pharmaceuticals, Inc. at 1-844-259-6783 or FDA at
1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections/sepsis.

References:

References:

  1. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  1. Data on file. Alexion Pharmaceuticals, Inc.
  2. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  1. Meisel A, et al; CHAMPION MG Study Group. J Neurol. 2023;270(8):3862-3875.
  2. Vu T, et al. NEJM Evid. 2022;1(5):1-22.
  3. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  4. Data on file. Alexion Pharmaceuticals, Inc.
  1. Data on file. Alexion Pharmaceuticals, Inc.
  2. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  3. Draft article 2.
  1. Data on file. Alexion Pharmaceuticals, Inc.
  2. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  1. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  2. Data on file. Alexion Pharmaceuticals, Inc.
  3. Muppidi S, et al; MG Composite and MG-QOL 15 Study Group. Muscle Nerve. 2011;44(5):727-731.
  4. Meisel A, et al; CHAMPION MG Study Group. J Neurol. 2023;270(8):3862-3875.
  5. Vu T, et al. NEJM Evid. 2022;1(5):1-22.
  1. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  2. Kulasekararaj AG, et al. Blood. 2019;133(6):540-549.
  3. Lee JW, et al. Blood. 2019;133(6):530-539.
  4. Vu T, et al. J Neurol. 2023;270(6):3129-3137.
  5. Kusner LL, et al. Ann N Y Acad Sci. 2012;1274(1):127-132.
  6. Meriggioli MN, et al. Lancet Neurol. 2009;8(5):475-490.
  7. Conti-Fine BM, et al. J Clin Invest. 2006;116(11):2843-2854.
  8. Howard JF Jr. Ann N Y Acad Sci. 2018;1412(1):113-128.
  9. Engel AG, et al. Mayo Clin Proc. 1977;52(5):267-280.
  10. Sahashi K, et al. J Neuropathol Exp Neurol. 1980;39(2):160-172.
  11. Murphy K, et al. Janeway's Immunobiology. 9th ed. Garland Science, Taylor & Francis Group, LLC;2017:37-76.
  12. Rother RP, et al. Nat Biotechnol. 2007;25(11):1256-1264.
  1. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  2. Meisel A, et al; CHAMPION MG Study Group. J Neurol. 2023;270(8):3862-3875.
  1. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  2. Centers for Disease Control and Prevention. Updated February 7, 2022. Accessed February 8, 2024. https://www.cdc.gov/meningococcal/about/soliris-patients.html
  3. Mbaeyi SA, et al; Advisory Committee on Immunization Practices. Centers for Disease Control and Prevention; 2020. Accessed February 8, 2024. https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm
  4. Centers for Disease Control and Prevention. Updated December 28, 2023. Accessed February 8, 2024. https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf
  5. Centers for Disease Control and Prevention. Updated November 23, 2023. Accessed February 8, 2024. https://www.cdc.gov/vaccines/vpd/mening/public
  6. Centers for Disease Control and Prevention. Updated November 20, 2023. Accessed February 8, 2024. https://www.cdc.gov/vaccines/vpd/mening/hcp/administering-vaccine.html
  1. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  2. Meisel A, et al; CHAMPION MG Study Group. J Neurol. 2023;270(8):3862-3875.
  3. Data on file. Alexion Pharmaceuticals, Inc.
  4. Vu T, et al. NEJM Evid. 2022;1(5):1-12.
  5. Howard JF Jr, et al. Poster presented at: 14th Myasthenia Gravis Foundation of America International Conference; May 10-12, 2022; Miami, FL.
  6. Habib AA, et al. Poster presented at: American Association of Neuromuscular & Electrodiagnostic Medicine Annual Myasthenia Gravis Foundation of America Scientific Session; September 21, 2022; Nashville, TN.
  7. Vu T, et al. J Neurol. 2023;(270):3129-3137.
  8. Jaretzki A III, et al. Neurology. 2000;55(1):16-23.
  1. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  2. Data on file. Alexion Pharmaceuticals, Inc.
  3. Meisel A, et al; CHAMPION MG Study Group. J Neurol. 2023;270(8):3862-3875.
  1. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  2. Conti-Fine BM, et al. J Clin Invest. 2006;116(11):2843-2854.
  1. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  2. Conti-fine BM, et al. J Clin Invest. 2006;116(11):2843-2854.
  1. Conti-Fine BM, et al. J Clin Invest. 2006;116(11):2843-2854.
  2. Howard JF Jr. Ann N Y Acad Sci. 2018;1412(1):113-128.
  3. Mantegazza R, et al. Immunotargets Ther. 2020;9:317-331.
  4. Anil R, et al. J Neurol Sci. 2020;414:116830.
  5. Tomschik M, et al. Neurology. 2020;95:10.e1426-e1436.
  6. Oh S. J Clin Neurol. 2009;5:53-64.
  7. Hendricks TM, et al. Am J Ophthalmol. 2019;205:99-105.
  8. Mercelis R, et al. Acta Neurol Belg. 2023;123:375-384.
  9. Guptil JT, et al. Neurotherapeutics. 2016;13(1):118-131.
  10. Li Y, et al. Cleve Clin J Med. 2013;80(11):711-721.
  11. Meriggioli MN, et al. Lancet Neurol. 2009;8(5):475-490.
  12. Engel AG, et al. Mayo Clin Proc. 1977;52(5):267-280.
  13. Sahashi K, et al. J Neuropathol Exp Neurol. 1980;39(2):160-172.
  14. Data on file. Alexion Pharmaceuticals, Inc.
  15. Vincent A, et al. UK Myasthenia Gravis Survey. J Neurol Neurosurg Psychiatry. 2003;74(8):1105-1108.
  16. Law, N., et al. Neurol Ther. 2021;10(1):1103-1125.
  17. Muppidi S, et al. Muscle Nerve. 2011;44(5):727-731.
  18. Myasthenia Gravis Foundation of America. Accessed April 1, 2024. https://myasthenia.org/portals/0/qmg.pdf
  19. Jaretzki A, et al. Ann Thorac Surg. 2000;70(1):327-334.
  20. Sharshar T, et al. JAMA Neurol. 2021;78(4):426-433.
  21. Sanders DB, et al. Neurology. 2016;87(4):419-425.
  22. Melzer J, et al. J Neurol. 2016;263:1473-1494.
  1. ULTOMIRIS. Prescribing information. Alexion Pharmaceuticals, Inc.
  2. Vu T, et al. NEJM Evid. 2022;1(5).
  3. Meisel A, et al; CHAMPION MG Study Group. J Neurol. 2023;270(8):3862-3875.
  4. Howard JF Jr. Ann N Y Acad Sci. 2018;1412(1):113-128.
  5. Kusner LL, et al. Ann N Y Acad Sci. 2012;1274(1):127-132.
  6. Meriggioli MN, et al. Lancet Neurol. 2009;8(5):475-490.
  7. Conti-Fine BM, et al. J Clin Invest. 2006;116(11):2843-2854.
  8. Data on file. Alexion Pharmaceuticals, Inc.